Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 20/20 | 0.73 |
| ▸ | ADRA1D | P25100 | 20/20 | 0.73 |
| ▸ | HTR1B | P28222 | 20/20 | 0.73 |
| ▸ | ADRA1A | P35348 | 20/20 | 0.73 |
| ▸ | ADRA1B | P35368 | 20/20 | 0.73 |
| ▸ | DRD2 | P14416 | 1/20 | 0.62 |
| ▸ | HTR2A | P28223 | 1/20 | 0.62 |
| ▸ | HTR2C | P28335 | 1/20 | 0.62 |
| ▸ | HTR7 | P34969 | 1/20 | 0.62 |
| ▸ | DRD3 | P35462 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL6834969 | 0.99 | HTR1A (0.72) | HTR1AADRA1DHTR1BADRA1AADRA1B | |
| Hydrochloric Acid SCHEMBL7722154 | 0.96 | HTR1A (0.68) | HTR1AADRA1DHTR1BADRA1AADRA1B | |
| SCHEMBL7715000 | 0.95 | HTR1A (0.66) | HTR1AADRA1DHTR1BADRA1AADRA1B | |
| SCHEMBL7715064 | 0.95 | HTR1A (0.66) | HTR1AADRA1DHTR1BADRA1AADRA1B | |
| Hydrochloric Acid SCHEMBL7719566 | 0.94 | HTR1A (0.65) | HTR1AADRA1DHTR1BADRA1AADRA1B | |
| SCHEMBL7676522 | 0.93 | HTR1A (0.63) | HTR1AADRA1DHTR1BADRA1AADRA1B | |
| SCHEMBL7720143 | 0.92 | HTR1A (0.62) | HTR1AADRA1DHTR1BADRA1AADRA1B | |
| Hydrochloric Acid SCHEMBL7722203 | 0.91 | HTR1A (0.60) | HTR1AADRA1DHTR1BADRA1AADRA1B | |
| SCHEMBL7719376 | 0.90 | HTR1A (0.60) | HTR1AADRA1DHTR1BADRA1AADRA1B | |
| SCHEMBL7722096 | 0.90 | HTR1A (0.60) | HTR1AADRA1DHTR1BADRA1AADRA1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2266570-A1 | Use of binding partners for 5-HT5 receptors for treating neurodegenerative and neuropsychiatric disorders | Abbott GmbH & Co. KG (DE) | 2010-12-29 | — | — | EP | disclosed |
| US-20040202656-A1 | Use of binding partners for 5-HT5 receptors for the treatment of neurodegenerative and neuropsychiatric disorders | ABBVIE DEUTSCHLAND GMBH & CO KG (DE) | 2004-10-14 | — | — | US | disclosed |
| EP-0927184-B1 | 3-SUBSTITUTED PYRIDO 4',3':4,5]THIENO 2,3-D]PYRIMIDINE DERIVATIVES, THEIR PREPARATION AND THEIR USE | ABBOTT GMBH & CO KG (DE) | 2003-10-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040202656-A1 | Use of binding partners for 5-HT5 receptors for the treatment of neurodegenerative and neuropsychiatric disorders | HTR5A, GRM5, GRIK5 | HTR1A 8/4885ADRA1D 1765/4885HTR1B 37/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.